NGF
Beta-nerve growth factor
As of the edition of 20 October 2026, NGF (beta-nerve growth factor, UniProt P01138) has 7 drugs tested at it and 8 companies on the list, 7 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P01138
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 10
- Disease areas
- Bones, joints and muscles; Nervous system; Inherited and neonatal; Urinary and reproductive; Pregnancy and women's health; Cancer; Hormones; Blood and lymph
- Registered trials of its drugs
- 70
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 3 |
| Stopped | 3 |
| Status not established | 1 |
| Total | 7 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Tanezumab | Stopped | Phase 3 | none listed |
| Fasinumab | Went quiet | Phase 3 | none listed |
| Fulranumab | Went quiet | Phase 3 | none listed |
| MEDI7352 | Stopped | Phase 2 | none listed |
| EP-9001A | Status not established | Phase 1 | none listed |
| MEDI-578 | Stopped | Phase 1 | none listed |
| PG-110 | Went quiet | Phase 1 | none listed |
7 of 7 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 7 |
| Undetermined | 1 |
| Total on the list | 8 |
| Company | Route |
|---|---|
| Pfizer | Route A |
| Regeneron | Route A |
| AstraZeneca | Route A |
The other 5 companies at NGF
In the product8 companies in all; 5 are not named here, and no score is.
See the 8 companies at NGF, ranked, with the facts behind eachRequest access. Nothing is shown until you do.